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ABSTRACT
Objectives: The purpose of this study was to evaluate the clinical and
economic beneﬁts of routine infant vaccination with seven-valent pneu-
mococcal conjugate vaccine (7vPCV) in Hong Kong.
Methods: A decision-analytic model was populated with local age-speciﬁc
incidence data to simulate the expected health outcomes resulting from
7vPCV vaccination of a birth cohort of 57,100 children compared with an
unvaccinated cohort over a 10-year horizon. Primary analyses were con-
ducted from a payer perspective, using local inpatient and outpatient costs
associated with the treatment of pneumococcal disease. Vaccine efﬁcacy
rates were consistent with results from pivotal clinical trials. The reduction
in adult invasive pneumococcal disease (IPD) and associated cost avoid-
ance due to the indirect effect of vaccination were estimated in line with
published overseas rates.
Results: Universal 7vPCV vaccination was estimated to prevent 524 cases
of IPD and more than 2580 cases of otitis media in the birth cohort over
a 10-year period, leading to a reduction of HK$28.7 million (US$3.7
million) in direct medical costs. Additional cost savings from the indirect
prevention of 919 adult cases of IPD during this time period also resulted.
Overall, 7vPCV vaccination was estimated to have an incremental cost per
life-year gained of HK$50,456 (US$6460) from a payer perspective
or HK$46,308 (US$5929) when both direct and indirect costs were
included.
Conclusion: With reference to the World Health Organization’s threshold
for cost-effectiveness, results from this study indicate that routine infant
vaccination with 7vPCV is a cost-effective intervention because of the
added cost savings resulting from the indirect effect of vaccination on
adult disease.
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Introduction
Pneumococcal disease, caused by the bacterium Streptococcus
pneumoniae, is a leading cause of vaccine-preventable death in
children less than 5 years of age worldwide [1]. Clinical presen-
tations may be invasive (meningitis, bacteremia, and bacteremic
pneumonia, collectively reported as invasive pneumococcal
disease [IPD]) or noninvasive (nonbacteremic pneumonia and
otitis media) depending on the site of infection. In Hong Kong,
pneumococcal disease is a major health-care burden, particularly
in young children and the elderly. In 2005, all-cause pneumonia
was recorded as the third most common cause of death (11.1%
of total deaths) in Hong Kong [2].
Although penicillin remains the drug of choice for patients
with pneumococcal disease, the growing incidence of antibiotic-
resistant S. pneumoniae is a concern worldwide and has com-
plicated disease management [3]. Furthermore, patients with
resistant pneumococcal infections often require greater resource
utilization, including longer hospital stays, to manage their con-
dition, highlighting the potential economic consequences of
increasing resistance rates of S. pneumoniae [4,5]. Several
studies conducted in Hong Kong have indicated rising resistance
rates of S. pneumoniae isolates obtained from children, with
one study reporting penicillin resistance as high as 58.2%
(29.5% intermediate, 26.1% resistant) in children attending day
care [6].
Following recommendation from the Strategic Advisory
Group of Experts on Immunization, the World Health Organi-
zation (WHO) considers that the pneumococcal conjugate
vaccine should be a priority for inclusion in national childhood
immunization programs to reduce the heavy burden of pneumo-
coccal disease worldwide [7]. The seven-valent pneumococcal
conjugate vaccine (7vPCV) is a heptavalent conjugate vaccine
that contains saccharides of the capsular antigen of S. pneumo-
niae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F individually
conjugated to a diphtheria CRM197 protein. In Hong Kong,
7vPCV is indicated for the active immunization of infants and
children against invasive IPD, pneumonia, and otitis media
caused by S. pneumoniae serotypes included in the vaccine.
In some countries where 7vPCV has been included in routine
vaccination schedules, surveillance data have indicated a reduc-
tion in disease in both vaccinated infants and also in unvacci-
nated individuals [8–13]. This effect is referred to as “herd
protection” or “herd immunity,” and is an important indirect
beneﬁt extended to adults following the routine vaccination of
children. In the United States, it is estimated that 7vPCV has
prevented more than twice as many cases of pneumococcal
disease through indirect effects than through its direct effect of
protecting vaccinated children [13].
Assessments of the cost-effectiveness of public health inter-
ventions are assuming increasing inﬂuence in assisting decision-
making in Hong Kong. With growing pressures on health-care
expenditure, an economic evaluation of the cost-effectiveness of
universal infant vaccination with 7vPCV will provide a useful
decision tool to justify whether vaccine introduction is a worth-
while public health intervention. The present study is the ﬁrst of
its kind in Asia. Against this background, the aim of this study
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was to evaluate the clinical and economic beneﬁts of universal
infant vaccination with 7vPCV for both children and adults in
Hong Kong.
Methodology
Data Collection
Epidemiological data. Age-speciﬁc incidence rates for pediatric
cases of pneumococcal meningitis, pneumococcal bacteremia,
all-cause pneumonia, and otitis media were obtained from pub-
lished literature [14–16]. The annual number of adult hospital-
izations for conﬁrmed pneumococcal cases of meningitis and
bacteremia were estimated from the Hong Kong Hospital
Authority (HA) (2005 data), a statutory body that manages all
public hospitals in Hong Kong. The burden of pneumococcal
pneumonia in adults was also estimated from the HA by includ-
ing all conﬁrmed pneumococcal cases and assuming that 32% of
unspeciﬁed cases were due to S. pneumoniae [17]. In the event
that an adult had both bacteremia and pneumonia upon admis-
sion, a single case of pneumococcal pneumonia was recorded.
Pediatric case fatalities for pneumococcal meningitis, pneu-
mococcal bacteremia, and all-cause pneumonia were derived
from 2006 death statistics from the Hong Kong Department of
Health [18]. It was assumed that no cases of otitis media resulted
in death. Adult deaths were assumed to only occur due to pneu-
mococcal pneumonia, with data obtained from the HA. Vaccine
efﬁcacy rates observed in the Northern California Kaiser Perma-
nente pivotal clinical trial were applied [19,20], namely, a 97.4%
reduction in episodes of pneumococcal meningitis and bacter-
emia, a 6% reduction in all-cause pneumonia, and a 7% reduc-
tion in all-cause otitis media for pediatric cases. Efﬁcacy rates
against pediatric cases of all-cause pneumonia and otitis media
were varied in secondary analyses, in line with published over-
seas effectiveness data, i.e., 39% reduction in all-cause pneumo-
nia [21] and 42.7% reduction in acute otitis media [22]. The
seven serotypes in 7vPCV were estimated to cover 88.6% of IPD
cases in children <2 years and 90.6% of IPD cases in children
aged 2 to 6 years in line with published local rates [23]. Vaccine
serotype coverage in children >6 years of age was assumed to be
42.3% [24]. The waning of vaccine-induced immunity was also
considered in the model by assuming that for a period of 5 years
after initial vaccination of the birth cohort, vaccine efﬁcacy
would decrease by 1% per year and by 3% annually for years 6
to 10 after initial vaccination [25].
Cost Data
The cost of pneumococcal disease was determined from a payer
perspective in the primary analysis. Local inpatient cost data
were collected from deidentiﬁed case records for pediatric
patients admitted to the Prince of Wales Hospital or the United
Christian Hospital with either IPD (n = 8), pneumonia (n = 22),
or otitis media (n = 18) from 2005 to 2006. These costs covered
the direct medical resources consumed in the treatment of pneu-
mococcal disease including hospitalization, physician consulta-
tion fees, medications, and diagnostic tests. Costs associated
with treating adult cases of pneumococcal disease, namely, 7
cases of meningitis, 53 cases of bacteremia, and 5327 cases of
pneumonia (all clinically conﬁrmed pneumococcal pneumonia
and 32% of all-cause pneumonia cases) in 2005 were obtained
from the HA and were used to estimate the weighted average
cost for the treatment for adults aged 20 to 34 years, 35 to 64
years, and 65 years. All costs were discounted by 5% in the
primary analysis.
The cost of pneumococcal disease was also determined from a
societal perspective in a secondary analysis to include all of the
direct medical expenses of the payer perspective combined with
two additional disease-related costs: direct nonmedical costs and
indirect costs. Nonmedical costs were included to reﬂect items,
such as transportation costs, incurred for physician visits and
hospital stays. Indirect costs reﬂected the opportunity cost of an
individual informally caring for a child with pneumococcal
disease and forsaking the use of their time for other economically
valuable purposes (e.g., employment). Costs were determined
through written surveys sent to 50 local physicians from different
regions in Hong Kong who had experience in the treatment of
pneumococcal disease. A total of 30 surveys were completed and
used for indirect cost estimations. The respondents were requested
to estimate the number of sick days that would be required after
discharge for each clinical presentation of pneumococcal disease.
The number of days a carer would be absent from work was
estimated as 50% of the length of hospital stay added to the
number of sick days required postdischarge. The median monthly
salary (HK$10,000) in 2006, obtained from the Hong Kong
Census and Statistics Department, was used to estimate the
average total wages lost for each clinical presentation of pneumo-
coccal disease.
The long-term treatment costs for complications experienced
by patients with meningitis, such as deafness, brain damage,
focal neurological deﬁcit, and chronic seizures, were considered
in a secondary analysis. The frequency of each complication was
assumed to be 4.3%, 9.7%, 6.0%, and 7.0%, respectively, in line
with published rates from the UK, as local estimates were not
available [26–28]. Published UK costs [24] for the treatment
of each form of sequelae were converted to Hong Kong dollars
(HK$) using the May 2008 exchange rate (GB£1 =
HK$14.1478) and inﬂated to present values, in the absence of
local costs. The breakdown of the costs included in the model is
presented in Table 1.
The cost of introducing a universal vaccination program
included both 7vPCV vaccine acquisition (HK$500 per dose) and
administration costs (HK$12.07 per injection). Vaccination was
assumed to be provided for the birth cohort, i.e., infants less than
6 months of age, as a primary series of three doses at 2, 4, and 6
months of age with a booster (fourth) dose administered in the
second year of life at 12 to 15 months of age. A vaccination
coverage rate of 95% was assumed for all infants.
Decision Analytic Model
To estimate the long-term outcomes associated with vaccination,
a previously developed decision analytic economic model [17,24]
was adapted to simulate the expected health outcomes resulting
from universal 7vPCV vaccination of a birth cohort of 57,100
infants in Hong Kong compared with no vaccination over a
10-year time horizon (Fig. 1). The cohort was divided into
6-month age bands, and infants less than 6 months of age were
further divided into those aged 0 to 2 months and 2 to 6 months.
The annual number of pneumococcal infections by clinical pre-
sentation in each age band was then calculated, in addition to the
reduction in cases that would be afforded with 7vPCV vaccina-
tion, and the mortality and cost resulting from these events.
Anticipated indirect (herd protection) effects of 7vPCV in unvac-
cinated adults were estimated by calculating the reduction in adult
cases of IPD in line with published rates from the US experience
[9,10]. Themidpoint estimates for the indirect effects were used in
the primary analysis, namely, 32% (range 23–41%) for adults
aged 20 to 34 years, 8% (range 1–20%) for adults aged 35 to 64
years, and 18% (range 11–31%) for adults aged 65 years.
Economic Evaluation of 7vPCV in Hong Kong S43
Cost-Effectiveness Analysis
The cost-effectiveness of a universal 7vPCV vaccination program
was calculated in terms of cost per life-year gained (CLYG).
Life-years were used to measure deaths avoided, where each
death prevented was equated to a certain number of life-years,
depending upon the age at which the death was expected to occur
and the life expectancy of the individual. Each death avoided
Table 1 Incidence, case fatality, and cost of pediatric cases of pneumococcal disease by clinical presentation
Parameter
Incidence per 1000
Pneumococcal
bacteremia
Pneumococcal
meningitis
All-cause
pneumonia Otitis media
<2 years [14,16] 0.042 0.019 10.475 34.7
(0–9 years)3–5 years [14,16] 0.021 0.006 8.477
6–10 years [15] 0.010 0.001 6.400
Mortality (%) [18] 4.6 9.0 0.2 0
Direct acute cost per infection (HK$) 68,641 103,408 42,149 4,206
Indirect cost per infection (HK$) 2,753 2,466 2,337 1,580
Long-term costs per disability
Unit costs
(HK$) [24]
Proportion of meningitis
cases affected (%)
Deafness 908,948 4.3 [26]
Brain damage 12,168,248 9.7 [27]
Focal neural deﬁcit 226,189 6.0 [28]
Chronic seizures 71,172 7.0 [28]
Source: Direct acute treatment costs were obtained from case records for pediatric admissions to the Prince ofWales Hospital or the United Christian Hospital in Hong Kong from 2005 to
2006. Indirect treatment costs were obtained from a survey of local physicians and the Hong Kong Census and Statistics Department (2006 data).
Figure 1 Decision analytic model simulating the expected health outcomes for a birth cohort of 57,100 infants in Hong Kong vaccinated with the 7-valent
pneumococcal conjugate vaccine compared with an unvaccinated cohort over a 10-year time horizon.
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from the birth cohort was equal to the average Hong Kong life
expectancy at 5 years of age (approximately 79 years) minus the
child’s age at the time of death as determined by the incidence of
IPD and its associated mortality. The average life expectancies of
adults aged 20 to 34 years (52.9 years), 35 to 64 years (31.7
years), and 65 years (8.3 years) were estimated from life tables
for 2006 from the Hong Kong Department of Health. The life-
years gained from preventing an adult’s death were equal to the
relevant life expectancy of the adult at the time the death was
avoided. In the primary analysis, life-years gained were dis-
counted at a rate of 5%.
A series of univariate sensitivity analyses were performed to
evaluate the sensitivity of the ﬁndings to plausible variation in
speciﬁc data inputs. Parameters varied were: indirect effects
(lower and upper 95% conﬁdence bound estimates used), vaccine
serotype coverage, vaccine efﬁcacy against IPD, all-cause pneu-
monia and otitis media, the incidence of each clinical presenta-
tion (meningitis, bacteremia, pneumonia, and otitis media), the
discount rate, the weighted average cost of treatment for pediat-
ric cases, and the cost per course of 7vPCV.
Results
Outcomes
The incidence of pediatric cases of pneumococcal disease by
clinical presentation is summarized in Table 1. Adult cases
obtained from the HA and the Hong Kong Department of Health
are shown in Table 2. The impact of 7vPCV vaccination with
respect to the number of cases of pneumococcal disease and
deaths avoided in the birth cohort, and the unvaccinated adult
populations is presented in Table 3. In the birth cohort alone,
universal 7vPCV vaccination was estimated to prevent 524 cases
of IPD (meningitis, bacteremia, and hospitalized cases of pneu-
monia), approximately 2580 cases of otitis media, and 2 deaths.
With the inclusion of the indirect effect of vaccination, a total of
1081 life-years were gained through the prevention of an addi-
tional 919 cases of IPD and 140 deaths in the adult population.
Costs
A summary of treatment costs saved as a result of 7vPCV vacci-
nation is presented in Table 4. All costs presented are discounted
at 5%. Overall, universal infant 7vPCV vaccination was esti-
mated to lead to a reduction of at least HK$28.7 million (US$3.7
million) in direct medical costs associated with treatment of the
birth cohort over 10 years. By expanding the analysis to include
the indirect effects of 7vPCV on the adult population, HK$56.6
million (US$7.3 million) in cost savings were estimated during
the time period. With the inclusion of indirect costs, HK$61.1
million (US$7.8 million) in cost savings resulted.
Cost-Effectiveness
The resulting incremental cost-effectiveness ratios for the
primary analysis are presented in Table 5. From a payer perspec-
tive, universal vaccination with 7vPCV had a discounted CLYG
of HK$50,454 (US$6460) when the indirect effects of vaccina-
tion on the adult population were taken into account. With the
inclusion of both direct and indirect costs, the discounted CLYG
decreased to HK$46,318 (US$5929).
Sensitivity Analyses
The results of the various univariate sensitivity analyses previ-
ously described are presented in Table 6. All incremental cost-
effectiveness ratios are calculated from both a payer and societal
perspective, and include both direct and indirect effects of vac-
cination. The CLYG was most sensitive to variations in assump-
tions regarding vaccine costs, indirect effects, incidence of all-
Table 2 Cost and frequency of adult cases of invasive pneumococcal disease by clinical presentation, 2005
Age (years)
Pneumococcal
bacteremia
Pneumococcal
meningitis
Pneumococcal
pneumonia
Deaths due
to pneumonia*
20–34 1 0 139 5
35–64 16 5 698 61
65 36 2 4,498 743
Weighted average direct
cost per infection
HK$32,190 (<65 years)
HK$30,120 (65 years)
*Assumed adult deaths because of pneumococcal pneumonia only.Total cases of pneumococcal pneumonia have been estimated by assuming that 32% of unspeciﬁed pneumonia was caused
by Streptococcus pneumoniae [17].
Source: Hong Kong Hospital Authority 2005.
Table 3 Estimated outcomes: cases, deaths, and life-years gained for the birth cohort and adults
Number of cases
7vPCV
vaccination (a)
No
vaccination (b)
Increment
(a–b)
Birth cohort
Bacteremia 7 20 -13
Meningitis 2 8 -6
All-cause pneumonia 9,022 9,527 -505
Otitis media 38,928 41,515 -2,587
Deaths 16 18 -2
Life-years lost 330 370 -40
Adults
All invasive pneumococcal disease 4,476 5,395 -919
Pneumococcal pneumonia deaths 668 808 -140
Life-years lost 5,224 6,265 -1,041
Total life-years lost 5,554 6,635 -1,081
7vPCV, seven-valent pneumococcal conjugate vaccine.
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cause pneumonia attributable to S. pneumoniae, and vaccine
efﬁcacy against all-cause pneumonia. Varying the vaccine efﬁcacy
rates for pediatric all-cause pneumonia and otitis media in line
with effectiveness data from the United States further reduced the
incremental cost-effectiveness ratios (Table 7). With the inclusion
of overseas long-term treatment costs for sequelae in meningitis
survivors (obtained from the UK), the CLYG decreased to
HK$44,644 (UK$5718) when only direct costs were included or
HK$40,496 (US$5189) when both direct and indirect costs were
considered.
Discussion
The WHO Choosing Interventions that are Cost-Effective group
has developed guidelines on generalized cost-effectiveness analy-
ses for public health interventions and indicates that interven-
tions which cost less than three times the average per capita
income per outcome unit are cost-effective [29]. With respect to
this threshold, universal 7vPCV vaccination would be considered
cost-effective in Hong Kong if the CLYG is below HK$680,007
(US$87,068) per life-year gained, using the 2007 gross domestic
product per capita of HK$226,669 [30]. Results from our study
indicate that universal 7vPCV vaccination is a cost-effective inter-
vention in Hong Kong with reference to this threshold from both
a payer and societal economic perspective.
A conservative incidence rate of bacteremia was employed in
the primary analysis, in line with recent hospitalization data [14],
namely, 4.2 per 100,000 person-years (in the 0–2 years age
group) and 2.1 per 100,000 person-years (in the 3–5 years age
Table 4 Estimated cost (HK$) of pneumococcal disease for pediatric and adult populations
Cost estimation
7vPCV
vaccination (a)
No
vaccination (b)
Increment
(a–b)
Direct costs only
Birth cohort
Vaccination cost 111,108,949 0 111,108,949
Direct cost 458,249,848 486,656,317 -28,406,470
Cost of death 2,228,524 2,509,036 -280,512
Total 571,587,320 489,165,354 82,421,966
Adults
Direct cost 136,388,287 164,274,090 -27,885,803
Total—infants and adults 707,975,607 653,439,444 54,536,163
Direct and indirect costs
Birth cohort
Vaccination cost 111,108,949 0 111,108,949
Direct and indirect costs 527,771,939 560,661,422 -32,889,483
Cost of death 2,228,524 2,509,036 -280,512
Total 641,109,412 563,170,459 77,938,953
Adults
Direct cost 136,388,287 164,274,090 -27,885,803
Total—infants and adults 777,497,699 727,444,549 50,053,150
Note: Figures may not sum because of rounding.
7vPCV, seven-valent pneumococcal conjugate vaccine.
Table 5 Incremental cost-effectiveness of 7vPCV vaccination from
payer and societal perspectives
Cost estimation scenarios
Cost per life-year
gained (HK$)*
Payer perspective
With indirect effects 50,456 (US$6,460)
No indirect effects 2,034,688 (US$260,523)
Societal perspective
With indirect effects 46,308 (US$5,929)
No indirect effects 1,924,019 (US$246,353)
*May 2008 exchange rate, US$ = HK$7.81. Source: http://www.xe.com.
7vPCV, seven-valent pneumococcal conjugate vaccine.
Table 6 Sensitivity analyses for payer perspective scenario
Parameter varied Range of values CLYG (HK$) (range)
Base case (with indirect effects) NA 50,456
Discount rate 0% to 10% 36,516 to 65,795
Cost of treatment of pediatric cases 20% 45,200 to 55,712
Cost of vaccine course HK$1960 to HK$2060 47,843 to 52,861
Lower 95% bound on indirect effects 23% (20–34 years), 1% (35–64 years), and 11% (65 years) 103,245
Upper 95% bound on indirect effects 41% (20–34 years), 20% (35–64 years), and 31% (65 years) 17,854
Vaccine serotype coverage 5% 50,311 to 50,601
Vaccine efﬁcacy against IPD 82.7% to 99.9% 50,394 to 50,820
Vaccine efﬁcacy against all-cause pneumonia 1.5% to 11% 36,034 to 72,849
Vaccine efﬁcacy against all-cause otitis media 4.1% to 9.7% 47,184 to 53,970
Incidence of meningitis 50% to 200% of base 49,429 to 50,976
Incidence of bacteremia 50% to 200% of base 49,103 to 51,144
Incidence of all-cause pneumonia 50% to 200% of base 33,197 to 59,301
Incidence of all-cause otitis media 50% to 200% of base Dominant—50,715
CLYG, Cost per life-year gained; IPD, invasive pneumococcal disease; NA, not applicable.
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group). Other local studies have reported higher incidence rates
of up to 20 per 100,000 children less than 5 years of age [31].
The inclusion of this rate in the primary analysis (when all other
variables remain unchanged) estimates that universal 7vPCV vac-
cination could prevent 105 cases of bacteremia over a 10-year
period, reducing the CLYG to HK$41,434 (US$5305) when only
direct costs are included or HK$37,399 (US$4789) when both
direct and indirect costs are considered.
This study is the ﬁrst pharmacoeconomic evaluation on the
predicted impact of infant vaccination with 7vPCV completed in
an Asian country and serves as a useful example, both in a local
context and for other decision-makers in the Asia Paciﬁc region,
on the potential beneﬁts of introducing this vaccine into the
national childhood immunization schedule. An economic evalu-
ation of new vaccines yet to be included on the Hong Kong
immunization schedule, which was recently completed by the
University of Hong Kong, found that 7vPCV was highly cost-
effective at an incremental cost of HK$50,000 per life-year saved
from a societal perspective or HK$59,000 from a payer perspec-
tive [32]. The assumptions in this study were similar to those
employed in our work; however, vaccine efﬁcacy rates differed
slightly for invasive disease (89.1%) and all-cause otitis media
(6.4%). With the inclusion of these rates in our model, the CYLG
increased slightly to HK$51,390 (US$6580) from a payer per-
spective or HK$47,512 (US$6033) from a societal perspective.
Overall, the investigators noted that the indirect effects of vacci-
nation had the greatest impact on the cost-effectiveness of 7vPCV
and that if it was assumed the vaccine also reduced the risk of
unvaccinated individuals from developing all-cause pneumonia,
the vaccine could be cost saving. The ﬁndings in this study were
considered by the Scientiﬁc Committee on Vaccine Preventable
Diseases under the Centre for Health Protection when they
recommended that 7vPCV should be included in the Hong
Kong childhood immunization program. This policy thus renders
Hong Kong the ﬁrst jurisdiction in Asia to implement routine
7vPCV vaccination for children.
The impact of routine infant vaccination on reducing adult
cases of pneumococcal disease is only one of the anticipated
indirect effects of 7vPCV. Data from the United States suggest
that signiﬁcant reductions in antibiotic prescribing for pediatric
cases of otitis media have occurred after licensure of 7vPCV in
2000 [22]. Similarly, a reduction in the incidence of antibiotic-
nonsusceptible IPD has also been reported and was attributed to
widespread 7vPCV vaccination [33]. This potential beneﬁt is of
signiﬁcant importance in Hong Kong and the Asia Paciﬁc region
where S. pneumoniae isolates are exhibiting increased antibiotic
resistance.
Study Limitations
The potential effect of vaccination on other clinical presentations
of pneumococcal disease, such as sinusitis and septic arthritis,
was not included in the analysis. Furthermore, the indirect
impact of vaccination on reducing the burden of all-cause pneu-
monia in adults was not considered due to limited access to local
records on the treatment of pneumonia in the community setting.
Another conservative approach adopted was only considering
the indirect impact of vaccination on pneumococcal pneumonia
deaths in adults. Potential reductions in deaths due to other
invasive presentations that may be afforded through herd pro-
tection were not included because of lack of available data.
Similarly, indirect effects in older children aged 10 to 19 years
were not considered in this analysis, as it was assumed that their
disease burden would be relatively low.
Indirect effects of vaccination depend on population factors,
such as contact structure and vaccination coverage, which vary
from country to country, and even within the same country from
year to year. Hence, it is possible that the indirect effects seen in
the United States may not accurately reﬂect the local indirect
effects, which could occur after routine uptake of 7vPCV in
Hong Kong. When considering that Hong Kong is densely popu-
lated, making it conducive to the spread of infectious diseases,
the indirect effect used in the study could be considered conser-
vative and perhaps could be much higher in reality. With that in
mind, routine infant vaccination with 7vPCV may be even more
cost-effective than we have estimated.
Conclusion
In Hong Kong, universal infant 7vPCV vaccination is expected to
lead to a substantial reduction in the incidence of all clinical
presentations of pneumococcal disease in both children and
adults. With reference to the WHO’s threshold for cost-
effectiveness, results from this study indicate the cost savings
from both the direct and indirect effects of vaccination render
7vPCV a cost-effective intervention and a worthwhile investment
to ensure that the population of Hong Kong is protected against
pneumococcal disease.
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